Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
Infection with hepatitis B virus (HBV) does not appear to independently affect pregnancy outcomes, although it contributes to prolonged infertility, higher odds of secondary infertility, ovulatory disorders and reduced implantation rate, a study has found.
Consuming polyphenol-rich pomegranate juice during pregnancy was associated with better microstructural development and functional connectivity in the brains of newborns with intrauterine growth restriction (IUGR), suggests preliminary evidence from a pilot randomized study.
Pregnancy attenuates the risk of endometrial cancer regardless of whether it ends shortly after conception or at 40 weeks of gestation, a study has shown. A biological process occurring within the first weeks of pregnancy drives this risk reduction, as shown by pregnancies terminated through induced abortions having similar risk reductions as those ending in childbirth.
Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.
Having identified the prevalence and increased risk of masked hypertension in pregnant women, a recent study suggests that an office blood pressure (BP) of at least 125/75 mm Hg in the second half of gestation may be appropriate to indicate out-of-office measurements in high-risk pregnancies.
Lower age at onset of first menstruation poses an increased risk of type 2 diabetes mellitus (T2DM) later in life, possibly driven by adult body mass index (BMI), whereas later menarche is associated with reduced diabetes risk, a study has found.
Young Singaporean women are likely to get themselves immunized against human papillomavirus (HPV) with the motivation to protect their own health, positive information about the vaccine and parental encouragement, as reported in a recent qualitative study.
The immunotherapeutic human papillomavirus (HPV) vaccine tipapkinogen sovacivec (TS) provided complete histologic resolution of cervical intraepithelial neoplasia (CIN) grade 2/3, offering a potential nonsurgical option for cervical precancerous lesions which could stretch to other HPV-associated precursors or cancers in the future, a new study shows.